Northwest Biotherapeutics secures $5.51 million loan from Streeterville Capital
NWBO•Northwest Biotherapeutics entered a $5.51 million loan agreement with Streeterville Capital on October 26, 2026. The loan carries 8% annual interest, a 10% original issue discount and a 22-month maturity.
1. Loan terms
The loan requires no repayments for eight months, followed by 14 equal monthly principal installments beginning June 26, 2027. Each installment requires payment of 110% of the pro rata principal amount, plus accrued interest. The company plans to use the proceeds for ongoing business operations, and may prepay at any time subject to a 10% charge.
